Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial

Background: More than 60% of oligo-recurrent prostate cancer (PCa) patients treated with metastasis-directed radiotherapy (MDRT) develop biochemical recurrence within 2 years. This recurrence rate emphasises the need for improved treatment and patient selection. In line with the treatment of primary...

Full description

Bibliographic Details
Main Authors: Aluwini, S. (Author), Brouwer, C.L (Author), de Jong, I.J (Author), Janssen, J. (Author), Langendijk, J.A (Author), Schuit, E. (Author), Smeenk, R.J (Author), Staal, F.H.E (Author), van Moorselaar, R.J.A (Author), Verzijlbergen, J.F (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
ADT
androgen
Androgen Antagonists
Androgens
antiandrogen
chronic disease
Chronic Disease
Clinical Trials, Phase III as Topic
human
Humans
male
Male
MDRT
Neoplasm Recurrence, Local
Oligometastasis
pathology
phase 3 clinical trial (topic)
Phase III
Positron Emission Tomography Computed Tomography
positron emission tomography-computed tomography
Prostate Cancer
prostate tumor
Prostatic Neoplasms
PSMA PET/CT
quality of life
Quality of Life
randomized controlled trial (topic)
Randomized Controlled Trials as Topic
Recurrence
SBRT
tumor recurrence
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items